Posted On August 6, 2026 /
By Debbie Muse / Posted in Blog
Texas Retina First in the US to Randomize a Patient in the i-SIGHT2 Bioelectric Therapy for Dry AMD Clinical Trial
The i-SIGHT2 pivotal clinical trial is evaluating the investigational i-Lumen AMD System for patients with intermediate to advanced dry age-related macular degeneration (AMD), and on July 1, 2026, Texas Retina’s Patrick D.
read more
Posted On August 4, 2026 /
By Debbie Muse / Posted in Blog
Dr. Abbey Participates in ReachMD CME on Sustained-Delivery TKIs for Wet AMD
Texas Retina’s Ashkan M. Abbey, MD, recently participated in a continuing medical education (CME) program through ReachMD, titled, “Redefining Durability in nAMD: The Science and Strategy of Sustained-Delivery TKIs.” During the program,
read more